ADAM17 and neoplasm: Not surprisingly the supra-additive response to the combined treatment modality of RT and inhibition of ADAM17 on the in vivo level point towards multiple mechanisms of action, including tumor cell- and TME-oriented ionizing radiation-sensitive processes.